| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Maduck Sean | Officer | C/O CORCEPT THERAPEUTICS INCORPORATED, 101 REDWOOD SHORES PARKWAY, REDWOOD CITY | /s/ Joseph Douglas Lyon, as attorney-in-fact for Sean Maduck | 04 Mar 2026 | 0001698310 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CORT | Common Stock | Award | +454 | +5.6% | $35.97* | 8,633 | 02 Mar 2026 | Direct | F1, F2, F3 | |
| transaction | CORT | Common Stock | Award | +454 | +5.3% | $0.000000* | 9,087 | 02 Mar 2026 | Direct | F3, F4 | |
| transaction | CORT | Common Stock | Tax liability | -110 | -1.2% | $35.97* | 8,977 | 03 Mar 2026 | Direct | F5, F6, F7 | |
| holding | CORT | Common Stock | 5,147 | 02 Mar 2026 | See Footnote | F8 | |||||
| holding | CORT | Common Stock | 20,570 | 02 Mar 2026 | See Footnote | F9 | |||||
| holding | CORT | Common Stock | 40,000 | 02 Mar 2026 | See Footnote | F10 | |||||
| holding | CORT | Common Stock | 34,000 | 02 Mar 2026 | See Footnote | F11 | |||||
| holding | CORT | Common Stock | 10,000 | 02 Mar 2026 | See Footnote | F12 |
| Id | Content |
|---|---|
| F1 | The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on March 2, 2026. |
| F2 | In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. |
| F3 | Includes 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025 and 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
| F4 | Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. |
| F5 | These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. |
| F6 | The closing price on March 2, 2026 was used to calculate the withholding obligation. |
| F7 | Includes 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025 and 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
| F8 | Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee. |
| F9 | Represents the shares held by MMM 2025, LLC of which the Reporting Person is a member and manager. |
| F10 | Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee. |
| F11 | Represents the shares held by SNM 2026 Grantor Retained Annuity Trust of which the Reporting Person is the trustee. |
| F12 | Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. |
President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.